News

As Zika looms, are LARCs the answer?


 

FROM MMWR

References

In U.S. states where mosquito-borne Zika virus transmission is possible, adult women at risk for unintended pregnancy and sexually active high school girls are primarily using moderately effective and less effective contraceptive methods, according to a report from the Centers for Disease Control & Prevention.

Long-acting reversible contraceptives (LARCs) – considered a highly effective method – are used by fewer than a quarter of nonpregnant women, about one-third of recently postpartum women, and fewer than one-tenth of sexually active high school girls, according to a report published Aug. 2 in the Morbidity and Mortality Weekly Report (doi: 10.15585/mmwr.mm6530e2).

Hormonal IUD Robert Boston/Washington University

Hormonal IUD

With locally transmitted cases of Zika virus infection increasing rapidly in Florida, the CDC is urging that the full range of FDA-approved contraceptive methods should be readily available and accessible to women who want to avoid or delay pregnancy.

“Given low rates of LARC use, states can implement strategies to remove barriers to the access and availability of LARC including high device costs, limited provider reimbursement, lack of training for providers serving women and adolescents on insertion and removal of LARC, provider lack of knowledge and misperceptions about LARC, limited availability of youth-friendly services that address adolescent confidentiality concerns, inadequate client-centered counseling, and low consumer awareness of the range of contraceptive methods available,” the CDC scientists wrote in the MMWR report.

Among nonpregnant women and recently postpartum women, the proportion not using any contraception ranged from 3.5% to 34.3%. Among sexually active high school girls, the proportion using no contraception ranged from 7.3% to 22.8%. The estimates of contraceptive use are based on 2011-2013 and 2015 survey data from four state-based surveillance systems.

The full MMWR report is available here.

mschneider@frontlinemedcom.com

On Twitter @maryellenny

Recommended Reading

Oral contraceptive efficacy unaffected by dimethyl fumarate
MDedge ObGyn
VIDEO: Expert roundtable explores 50 years of contraception
MDedge ObGyn
Study confirms role of oral contraceptives in preventing ovarian cancer
MDedge ObGyn
AAP, NASPAG issue joint guidance on menstruation management in teens with disabilities
MDedge ObGyn
Condom basics
MDedge ObGyn
Supreme Court will not hear pharmacy religious liberty case
MDedge ObGyn
Dapivirine vaginal ring sharply reduces HIV infection risk
MDedge ObGyn
The role ob.gyns. can play in preventing Zika virus
MDedge ObGyn
Webcast: Hormonal contraception and risk of venous thromboembolism
MDedge ObGyn
ACOG: Offer immediate postpartum LARC as option
MDedge ObGyn